Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

April 29, 2024

Study Completion Date

April 30, 2026

Conditions
Familial Chylomicronemia
Interventions
DRUG

Plozasiran

ARO-APOC3 injection

DRUG

Placebo

sterile normal saline (0.9% NaCl)

Trial Locations (58)

1010

NZCR OPCO Ltd, Auckland

2025

Middlemore Clinical Trials, Auckland

2050

Royal Prince Alfred Hospital, Camperdown

2065

Royal North Shore Hospital, St Leonards

2650

Universitair Ziekenhuis Antwerpen (UZA), Edegem

3000

Universitaire Ziekenhuizen Leuven, Leuven

3004

Baker Heart and Diabetes Institute, Melbourne

3081

Austin Health, Melbourne

3600

Instituto Modelo de Gastroenterologia, Formosa

4000

Centre Hospitalier Universitaire (CHU) de Liege, Liège

4103

Universitaetsklinikum Leipzig, Leipzig

6009

Linear Clinical Research Ltd, Nedlands

7740

Universitaetsklinikum Jena, Jena

8011

New Zealand Clinical Research, Christchurch

8036

Medizinische Universitaet Graz, Graz

9000

University Hospital Ghent, Ghent

10000

University Hospital Center Zagreb -Rebro, Department for Metabolic Diseases, Zagreb

10016

New York University Langone Medical Center, New York

10029

Icahn School of Medicine at Mt. Sinai, New York

11000

Clinical Center of Serbia, Institute of Endocrinology, Diabetes and Metabolic Diseases, Belgrade

11650

Centro Especializado en Diabetes Obesidad y Prevención de entermedades Cardiovasculares (CEDOPEC), Mexico City

13385

AP-HM-Hopital de La Conception, Marseille

14000

National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ), Tlalpan

15001

Hospital Abente y Lago, A Coruña

15706

Hospital Clinico Universitario de Santiago, Santiago de Compostela

18000

Clinical Centre Nis, Niš

18012

Complejo Hospitalario Universitario de Granada - Hospital Universitario Virgen de las Nieves, Granada

21075

Centennial Medical Group, Elkridge

23510

York Clinical Research, LLC, Norfolk

28007

Hospital General Universitario Gregorio Maranon, Madrid

30024

Herman Clinical Research, LLC, Suwanee

33434

Excel Medical Clinical Trials, LLC, Boca Raton

35100

Ege University Hospital Department Of Infectious Diseases, Izmir

38030

Erciyes University Faculty of Medicine, Melikgazi

46290

Ascension St. Vincent Cardiovascular Research Institute, Indianapolis

61469

Chonnam National University Hospital, Gwangju

62250

Instituto de Diabetes Obesidad y Nutrición S.C., Cuernavaca

63110

Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, St Louis

75013

AP-HP Hopital Pitie-Salpetriere, Paris

78731

Texas Diabetes and Endocrinology, Austin

119074

National University Hospital, Singapore

9112001

Hadassah Medical Center Ein Karem, Jerusalem

X5003DCE

Instituto Medico DAMIC, Córdoba

N6A 5B7

Robarts Research Institute, London

M5G 2C4

Toronto General Hospital, Toronto

G7H 7K9

Ecogene-21, Chicoutimi

H2W 1R7

Institute de Recherches Cliniques de Montreal, Montreal

G1V 4W2

Clinique des Maladies Lipidiques de Quebec Inc., Québec

H91 YR71

University Hospital Galway, Galway

260-8677

Chiba University Hospital, Chiba

920-8641

Kanazawa University Hospital, Ishikawa

598-0048

Rinku General Medical Center, Osaka

329-0498

Jichi Medical University Hospital, Tochigi

113-8655

Tokyo University Hospital, Tokyo

Unknown

Nippon Medical School Hospital, Tokyo

Sultan Qaboos University Hospital, Muscat

93-338

Instytut Centrum Zdrowia Matki Polki, Lodz

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY